

SCIENTIFIC REPORTS

OPEN

φ BO1E, a newly discovered lytic bacteriophage targeting carbapenemase-producing *Klebsiella pneumoniae* of the pandemic Clonal Group 258 clade II lineage

Marco Maria D'Andrea^{1,2}, Pasquale Marmo³, Lucia Henrici De Angelis¹, Mattia Palmieri¹, Nagaia Ciacci^{1,3}, Gustavo Di Lallo³, Elisa Demattè¹, Elisa Vannuccini⁴, Pietro Lupetti⁴, Gian Maria Rossolini^{1,2,5} & Maria Cristina Thaller³

The pandemic dissemination of KPC carbapenemase-producing *Klebsiella pneumoniae* (KPC-KP) represents a major public health problem, given their extensive multidrug resistance profiles and primary role in causing healthcare-associated infections. This phenomenon has largely been contributed by strains of Clonal Group (CG) 258, mostly of clade II, which in some areas represent the majority of KPC-KP isolates. Here we have characterized a newly discovered lytic *Podoviridae*, named φ BO1E, targeting KPC-KP strains of clade II lineage of CG258. Genomic sequencing revealed that φ BO1E belongs to the *Kp34virus* genus (87% nucleotide identity to vB_KpnP_SU552A). φ BO1E was stable over a broad pH and temperature range, exhibited strict specificity for *K. pneumoniae* strains of clade II of CG258, and was unable to establish lysogeny. In a *Galleria mellonella* infection model, φ BO1E was able to protect larvae from death following infection with KPC-KP strains of clade II of CG258, including one colistin resistant strain characterized by a hypermucoviscous phenotype. To our best knowledge φ BO1E is the first characterized lytic phage targeting *K. pneumoniae* strains of this pandemic clonal lineage. As such, it could be of potential interest to develop new agents for treatment of KPC-KP infections and for decolonization of subjects chronically colonized by these resistant superbugs.

Resistance to antibiotics that for decades were successfully employed to treat bacterial infections has reached an alarming level, and we are increasingly challenged by multidrug resistant (MDR) or extremely drug resistant (XDR) pathogens for which very few effective therapeutic alternatives remain available^{1,2}. This phenomenon has become so widespread and worrisome that some international organizations forecast, for the 21st century, the advent of a post-antibiotic era in which even common infections could be very difficult if not impossible to manage^{3,4}. In addition, as a result of globalization and increasing international mobility, antibiotic-resistant microorganisms tend to disseminate rapidly through different countries and, sometimes, evolve into real pandemics.

One of the most worrisome resistant pathogens undergoing pandemic dissemination is represented by *Klebsiella pneumoniae* producing KPC-type carbapenemases (KPC-KP), which very frequently show an MDR or even an XDR phenotype, including last resort molecules such as colistin. KPC-KP have spread rapidly and became endemic in several countries (e.g. USA, China, Taiwan, Israel, Greece, Italy and Colombia), where they are now a major cause of healthcare-associated infections correlated with high morbidity and mortality rates⁵⁻¹⁰.

¹Department of Medical Biotechnologies, University of Siena, Siena, Italy. ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. ³Department of Biology, University of Rome "Tor Vergata", Rome, Italy. ⁴Department of Life Sciences, University of Siena, Siena, Italy. ⁵Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy. Correspondence and requests for materials should be addressed to M.M.D. (email: marco.dandrea@unisi.it)




Figure 1. Comparison of the ϕ BO1E genome with KP34, the type phage of the *Kp34virus* genus, and with vB_KpnP_SU552A, the closest homologous deposited in public nucleotide databases. For each phage the corresponding accession numbers and the size in Kb are reported on the left. Long terminal repeats (LTR) are indicated by red squares.

The pandemic diffusion of KPC-KP was largely contributed by isolates belonging to few sequence types (STs), commonly ST11, which is the most prevalent KPC-KP detected in Asian countries (particularly in China and Taiwan)^{11, 12}, and ST258 and variants thereof (e.g. ST512, ST554 and ST1879), collectively included in Clonal Group 258 (CG258), that experienced a wider dissemination⁷. Recent studies demonstrated that strains of ST258 are hybrid clones originated by a number of large genomic recombination events that gave rise to two major clades (clade I and clade II), characterized mainly by different capsule polysaccharide (CPS) gene clusters^{13–15}. Clade II strains contribute to the majority of ST258 and of other STs of CG258 causing outbreaks reported in several regions including USA, Italy, South America, Israel and Greece^{14, 16–20}.

Bacteriophages, which in the pre-antibiotic era were successfully used for the treatment of bacterial infections, were recently reevaluated to fight some infections, especially those sustained by MDR bacteria. The present work describes the isolation and characterization of a newly discovered lytic bacteriophage able to specifically lyse strains of *K. pneumoniae* of CG258 clade II, which is of potential interest to develop new bacteriophage-derived agents against KPC-KP.

Results

Isolation and preliminary characterization of phage ϕ BO1E. Phage ϕ BO1E was isolated in September 2013 from the wastewater system of a large tertiary-care teaching hospital located in central Italy, where KPC-KP have been endemic since 2011. Screening of untreated wastewaters for the presence of phages able to lyse the *K. pneumoniae* ST258 clade II test strain KKBO-1 resulted in several plaques that differed in size, all surrounded by a hazy halo zone, suggesting the ability by these phages to produce soluble, polysaccharide-degrading enzymes²¹. Three plaques, characterized by different morphology, were purified and amplified for further analysis, as described in the methods section. The restriction analysis of phage DNA obtained from the three selected preparations with HindIII and BamHI showed an identical profile, suggesting that the phages were identical or very similar to each other, and that their genomes were made by a double-stranded DNA molecule of approximately 40–45 Kb. One phage was selected for further characterizations and named ϕ BO1E.

ϕ BO1E genome sequencing and analysis. High-throughput DNA sequencing of the whole phage genome and resolution of the 5'- and the 3'-ends performed by Sanger sequencing showed that the ϕ BO1E genome was 43,865 bp long, with a GC content of 53.8% and two direct repeats of 224 bp located at the 5'- and 3'-ends.

Bioinformatic analysis revealed 59 open reading frames (ORF) (Supplementary Table S1), all encoded on the same DNA strand (Fig. 1). Comparison with phages genomes deposited in the International Nucleotide Sequence Database Collaboration (INSDC) databases revealed that ϕ BO1E is a newly discovered bacteriophage most closely related with the *K. pneumoniae* vB_KpnP_SU552A phage (overall nucleotide identity, 87%), a member of the *Podoviridae* family, *Autographivirinae* subfamily²². Similar to vB_KpnP_SU552A, ϕ BO1E encoded a single subunit RNA polymerase, a common characteristic among members of the *Autographivirinae* subfamily, retained the same predicted host and phage promoters as well as a putative rho-independent transcriptional terminator, and was characterized by a lysis module composed by spanin-, holin- and endolysin-encoding genes located next to each other at the 3'-end of the phage genome. Altogether, these findings suggested that ϕ BO1E belongs to the newly proposed genus *Kp34virus*, recently approved by the International Committee on Taxonomy of Viruses^{22, 23}.

Electron microscopy. Results of analysis performed with transmission electron microscopy (TEM) showed that ϕ BO1E has morphological features typical of the members of the family *Podoviridae* and order *Caudovirales*, characterized by a head of icosahedral symmetry with a diameter of approximately 50 nm and a short tail of




Figure 2. Transmission electron micrograph of phage φ BO1E negatively stained with uranyl acetate. The bar indicates 50 nm.




Figure 3. (a) Influence of pH towards the infection ability of φ BO1E. Phage suspensions were incubated for 1 hour at the different pH values indicated by diamonds. (b) Effect of temperature towards the infection ability of φ BO1E. Results obtained with different temperatures, and times of incubations are shown. In both cases data are the mean of three independent experiments. Vertical black bars represent one standard deviation.

8–10 nm (Fig. 2). This result was consistent with the estimated size of the genome, considering that *Podoviridae* generally have a genome of about 38–45 Kb.

Determination of φ BO1E bacterial host range. Results from spot tests, carried out with a collection of 82 clinical strains of different clonal lineages and capsular types of *K. pneumoniae* (Supplementary Table S2) demonstrated that φ BO1E has a unique lytic specificity towards strains belonging to clade II of CG258 (e.g. ST258, ST512, ST554 and ST1879) and characterized by a CPS_{KKBO-4}/*wzi154*-type capsular gene cluster, all of which were lysed ($n = 43$). Strains having different CPS ($n = 39$), including those of ST258 clade I (CPS_{KK207-2}/*wzi29*-K41-type), were not sensitive to the action of the phage particles (Supplementary Table S2). The ability of φ BO1E to exclusively lyse CG258 clade II strains, but not those of CG258 clade I, suggests that the cell structures recognized by the phage are components of the capsular polysaccharide, since the main difference between the two clades is the production of a different type of CPS^{13,14}.

Sensitivity of φ BO1E to temperature and pH. Results of experiments performed to assess stability of phage particles to temperature and pH demonstrated that φ BO1E was stable within a wide range of conditions. In particular, a notable decrease of the infective capacity (≥ 2 log) was observed only after incubation at pH < 4 or > 9 (Fig. 3a), or after incubation at a temperature $\geq 50^\circ\text{C}$ for at least 60 minutes (Fig. 3b). These results demonstrated that φ BO1E is more stable to temperature than previously described phages of the *Kp34virus* genus, which after 10 minutes at 60°C exhibited a remarkable decrease in titer²².

Determination of phage life cycle. Plaques of φ BO1E on the indicator strain KKBO-1 showed a clear appearance, with no colonies growing inside the halos, suggesting a lytic nature of the phage. To assess the




Figure 4. One-step growth curve of bacteriophage ϕ BO1E. Ratios between PFU and the number of infected bacterial cells at different times are shown. Data are the mean of three independent experiments. Vertical black bars represent one standard deviation.




Figure 5. Kaplan–Meier survival curves of *Galleria mellonella* larvae infected with 10^7 cells of KKBO-1 (a) or KP04C62 (b) and treated with phage ϕ BO1E at a Multiplicity of Infection (MOI) of 10 or 100 at 30 minutes post-infection. Results obtained with control larval groups with the same amount of bacterial cells but not treated with phage are also shown. Abbreviations are as follow: PBS, phosphate buffered saline; SM, Salt Medium.

possibility of lysogenization, bacterial cells were infected for two rounds with ϕ BO1E at increasing multiplicity of infection (MOI), as described in the methods section. The cells which survived this exposure were confirmed to be phage-resistant because PCR screening with primers specific to the ϕ BO1E depolymerase gene yielded no amplicons. Altogether these results demonstrated that cells were not ϕ BO1E lysogens and that the phage is unable to lysogenize its *K. pneumoniae* host.

One-step growth experiments. Results of burst-size experiments, reported in Fig. 4, showed that the phage is characterized by a relatively short latency period (approximately 10 minutes). The period of increase of the phage progeny was about 20 minutes before a plateau level is reached at about 30 minutes. The computed burst-size was of ≈ 300 phage particles per infected cell.

Protection from infection in the *G. mellonella* infection model. To verify the possible *in vivo* efficacy of ϕ BO1E in protecting against infection, the *G. mellonella* wax moth larvae model was employed. Larvae were injected with suspensions of two well characterized KPC-KP strains of the CG258 clade II, KKBO-1 and KP04C62^{24,25}. The former strain is a representative of the major KPC-KP clone circulating in Italy during the early phases of the epidemic¹⁷, while the latter is a representative of ST512, which emerged subsequently and currently is one of the most prevalent KPC-KP clones circulating in Italy¹⁶. The latter strain is also colistin resistant and exhibits a hypermucoviscous phenotype²⁵.

In the *G. mellonella* model, both strains exhibited a very similar lethal dose 50% (LD₅₀) (KKBO-1, log LD₅₀: 6.02 ± 0.09 CFU; KP04C62, log LD₅₀: 6.1 ± 0.05 CFU)^{25,26}. Experiments of phage protection, performed with a tenfold LD₅₀ bacterial challenge (10^7 CFU), revealed that treatment with ϕ BO1E was overall capable of protecting

G. mellonella from lethal infection (Fig. 5), even if with differences between the two strains. In fact, with KKBO-1 differences in mortality rates obtained with MOI 10 was not significant (difference of 14% at 72 h, $p = 0.4698$), while a significant protection was observed using an MOI of 100 (difference of 34% at 72 h, $p = 0.0023$) (Fig. 5a). Conversely, with KP04C62 significant protection was observed with both MOIs (Fig. 5b; difference at 72 h of 43%, $p < 0.0001$ and 35%, $p < 0.0001$ with MOI 10 and 100, respectively). The reasons for this difference remain unknown. Possible explanations could be: i) the effect of the phage is easier to observe with KP04C62 because larvae die faster or ii) a reduction of the capsule-mediated virulence of the KP04C62 strain connects to the activity of the phage virion-associated depolymerase.

Discussion

The advent of antibiotic resistance crisis, with the global dissemination of bacterial pathogens which are resistant to most of the available therapeutic options, has renewed the interest for alternatives to antimicrobial compounds. The use of lytic bacteriophages as antibacterial agents had been considered in the early 1900s²⁷, and then largely abandoned in favor of antibiotics. Recently however phages, or components thereof, have been reconsidered with interest as potential antibacterial agents^{28–30}. Advantages of bacteriophages and their components include activity against antibiotic resistant bacteria and targeting of a very narrow-spectrum of infecting pathogens, with minimal impact on the resident microbiota.

The φ BO1E phage described in this work is a newly discovered lytic bacteriophage of the *Podoviridae* family able to specifically lyse CG258 KPC-KP of clade II. To the best of our knowledge this report constitutes the first example of a lytic phage that specifically targets this lineage. Indeed, other bacteriophages against KPC-KP of the *Podoviridae* and *Myoviridae* families have been previously described, but their target specificity was not investigated^{31,32}.

The phage described in this work is characterized by a number of favorable features, such as a notable stability to a wide range of pH and temperatures, a strict lytic nature, and the absence in its genome of genes encoding potential toxins. These features provide a strong rationale for the possible use of this phage or proteins thereof against KPC-KP strains belonging to the CG258 clade II lineage.

Indeed, KPC-KP of CG258 were shown to be among the major drivers for the KPC-KP pandemic, with a predominance of clade II strains^{14,16,20}. Under these circumstances, the lytic bacteriophage described in this work could be of relevant interest as a tool for decolonization of mucosal surfaces or even for the treatment of some infections and it could be used, alone or in phage-cocktails, to treat patients according to protocols of personalized medicine^{33,34}.

The efficacy of φ BO1E in reducing mortality of *G. mellonella* larvae infected by KPC-KP of CG258 clade II supports a potential utility of this phage for the above mentioned applications, although further experiments using different MOIs, times of phage administration and animal hosts (e.g. mouse model) will be necessary to confirm this hypothesis.

The specificity of φ BO1E for this clade suggests that the phage recognizes specific structures exposed on the capsular polysaccharide, given the fact that the major difference between the ST258 clades is the expression of distinct CPS and that it was recently demonstrated that strains of both CG258 clades express an identical lipopolysaccharide, termed D-galactan III³⁵. The characterization of the molecular targets recognized by φ BO1E will be of paramount importance both to elucidate the infection process of the phage and also to understand the mechanisms leading to resistance to infection, and will be the subject of future investigations. In addition, it would also be interesting to test phages related to φ BO1E for their host-spectrum against CG258 strains.

Materials and Methods

Bacterial strains. The clinical isolate KKBO-1, a previously characterized KPC-KP strain of ST258 clade II^{14,24}, was used as host for phage isolation and propagation. The same strain, along with the clinical isolate KP04C62, a KPC-KP strain of ST512 clade II that was also colistin-resistant and expressed an RmpA-independent hypermucoviscous phenotype, were used in the *G. mellonella* infection experiments.

Phage isolation. Bacteriophage φ BO1E was recovered from untreated hospital wastewaters by using the top-agar (lysogeny broth (LB) with 0.7% agar (Oxoid, Hampshire, UK)) overlay method and KKBO-1 as indicator strain, as previously described²³ with some modifications. Briefly, 40 ml of wastewaters were centrifuged at $3,850 \times g$ at 25 °C for 10 minutes. The supernatant was then filtered sequentially through 0.45 μ m and 0.22 μ m filters and diluted 1:100 in sterile ddH₂O. An aliquot of 100 μ l of this dilution was then used in the top-agar overlay experiment. Three rounds of infection and picking of isolated plaques were performed to obtain pure bacteriophage suspensions.

Determination of the host spectrum. The ability of φ BO1E to target different clones of *K. pneumoniae* was assessed by the spot test technique, using 82 previously characterized KPC-KP clinical strains (Supplementary Table S2), as previously described³⁶.

Large-scale production of bacteriophage suspensions. Amplification of bacteriophage φ BO1E was performed as follows. An overnight (O/N, corresponding to 12–18 hours) culture of KKBO-1 in LB broth, concentrated to 1/10 of its initial volume in salt medium (SM) buffer³⁷ (final volume 200 μ l), was mixed with 100 μ l of a bacteriophage suspension with a titer of 10^8 PFU/ml. After incubation for 30 minutes at 37 °C, 5 ml of molten top-agar were added and the obtained mixture was poured onto an LB agar (LBA) plate. Ten LBA plates were prepared and, following an O/N incubation at 37 °C, 4 ml of SM buffer were added to each plate. Subsequently, after 2 hours of incubation at room temperature (RT) with gentle shaking, the top-agar layer together with SM buffer

were recovered using a scraper. The obtained mixture was finally centrifuged, and the supernatant was decanted, filtered through 0.22 μm filter and stored at 4 °C.

Electron microscopy. A bacteriophage suspension containing $\approx 10^{12}$ PFU/ml, obtained by centrifugation at $25,000 \times g$ for 60 minutes of 10 ml of the mixture from large-scale production of the phage, followed by resuspension of the pellet in 100 μl of SM buffer (pH = 7.5), was used for electron microscopy analysis. Preparations of bacteriophages particles were processed by standard negative stain³⁸, and observed by a FEI Tecnai 12 (FEI, Eindhoven, The Netherlands) TEM fitted with an Osis Morada 2X4K CCD camera (Olympus, Shinjuku, Tokyo, Japan). In detail, 10 μl of the concentrated phage suspension were let to adsorb on a carbon-coated matrix and then stained with 2% uranyl acetate for 15 seconds. The grid was subsequently washed 2 times with ddH₂O, air dried and imaged by TEM.

Sensitivity to physical agents. Stability of φBO1E at different temperatures was determined by diluting phage particles to a final concentration of $\approx 10^9$ PFU/ml in a final volume of 1 ml of SM buffer. The aliquots were incubated at 25 °C (control), 37 °C, 40 °C, 50 °C and 60 °C, for 10, 20, 40 and 60 minutes. After incubation, the phage suspensions were titrated. Stability of φBO1E at different pH values was determined by diluting phage particles to a final concentration of 5×10^8 PFU/ml in SM buffer previously brought to different pH values using 1 M NaOH or 1 M HCl, to create a pH range from 3 to 11 with intervals of 1 unit. Phage suspensions were incubated for 60 minutes at 25 °C and then titrated. Assays for the determination of the stability to temperature and pH were made in triplicate and the reported values are the mean of the observations \pm standard deviation.

Determination of burst-size. The burst-size of the φBO1E phage, representing the average number of phages released by each bacterium after the lysis, was determined as follows. The indicator strain KKBO-1 was inoculated in 5 ml of LB and the inoculum was grown under aerobic conditions at 37 °C until the exponential phase of growth ($\text{OD}_{600} = 0.3\text{--}0.4$). An aliquot of 1 ml of the inoculum was then centrifuged at $13,000 \times g$ for 5 minutes and the pellet was resuspended in 1 ml of SM buffer. To 0.9 ml of this suspension 0.1 ml of the phage lysate at a concentration of 1×10^7 PFU/ml was added, in order to achieve an MOI of 0.01. The mixture was incubated for 10 minutes in a water-bath at 37 °C with shaking, centrifuged at $13,000 \times g$ for 4 minutes at RT and resuspended in 1 ml of SM buffer to remove any non-adsorbed phages. This preparation was then diluted 1:10,000 in LB medium (10 ml) and incubated in a water-bath at 37 °C. Aliquots of 0.1 ml were sampled after 10, 20, 25, 30, 40, 50, 60 and 70 minutes. Each aliquot was added to 4.5 ml of top agar, mixed, poured onto an LBA plate and incubated O/N at 37 °C. The latency period was defined as the time between infection (excluding the 15 minutes of pretreatment) and the shortest incubation time allowing the production of phages³⁹. The burst-size was calculated as the ratio between the number of phage particles released at the *plateau* level and the initial number of infected bacterial cells. Experiment was performed three times and the reported values are the mean of the observations \pm standard deviation.

Lysogeny verification. To verify the tentative temperate nature of the isolated phage, exponentially growing cultures of KKBO-1 in LB broth were infected with phages at an MOI of ~ 1 and incubated at 37 °C with shaking at 200 rpm for 24 hours. The infected culture was then diluted 1:100 in LB broth and phage stock suspension was added at an MOI $> 1 \times 10^4$. After 1 hour of incubation at 37 °C with shaking at 200 rpm, 0.1 ml were plated on LBA and incubated O/N at 37 °C, thus allowing the growth of presumptive φBO1E lysogen cells. Nine single colonies were picked and isolated in pure cultures. Resistance against φBO1E infection was tested by spotting 5 μl of the phage stock suspension (corresponding to 5×10^7 PFU) on LB agar plates overlaid with 4.5 ml top-agar containing the presumptive φBO1E lysogens. Obtained colonies were re-identified at the species level, investigated by multiplex PCR assay for *cps* genotyping¹⁴ and subjected to PCR amplification using primers targeting the φBO1E depolymerase gene (CDS59_F 5'-ATGAATTTAGTAAAAGCAAAGTATCCG-3' and CDS59_R 5'-CTAGAAAGCTGCCTGGGTATC-3').

DNA isolation and restriction endonuclease analysis. Extraction of the phage genomic DNA was performed using the Wizard[®] DNA Clean-Up System (Promega, Madison, WI, USA), following manufacturer recommendations. The exact determination of phage genomic DNA concentrations was carried out using a NanoDrop apparatus (Nanodrop Technologies Inc., Wilmington, USA), following the instructions provided by the manufacturer. Phage DNA preparations were digested with HindIII and BamHI restriction endonucleases (New-England Biolabs, MA, USA) for 8–10 hours. Restriction fragments were separated by electrophoresis in 0.75% agarose gel, stained with ethidium bromide and visualized under ultra-violet light to roughly estimate the genome size.

Genome sequencing. The genome of φBO1E was sequenced using a MiSeq instrument (Illumina Inc., San Diego, CA, USA) and a paired-ends approach (2×250 bp) with the kit Illumina Nextera[™]. Characterization of the ends of the phage genome was performed by direct Sanger sequencing of bacteriophage DNA, using the primers BO1E_2F (5'-TTGACTACGTCGGGATAGGC-3') and BO1E_1R (5'-AGCACTAGCGATAGCCAGTG-3'), as described elsewhere⁴⁰.

Bioinformatic analysis. Reads obtained by high-throughput sequencing were trimmed using Dynamic-Trim.plscript with a h value of 30 and assembled using the ABySS software^{41,42}. A single contig of 43.8 Kb was thus obtained and annotated using the RAST web-service⁴³. Automatic annotation was manually reviewed by BLASTP analysis against Refseq proteins deposited in INSDC databases. Conserved protein domains were searched for by using the web based CD-Search tool⁴⁴, and results were filtered to remove non-specific hits. Putative host and phage promoters, and rho-independent transcriptional regulators were annotated by comparison with the

closest homologs deposited in the INSDC databases: KP34 (Accession number: NC_013649), vB_KpnP_SU503 (Accession number: KP708985), vB_KpnP_SU552A (Accession number: KP708986), NTUH-K2044-K1-1 (Accession number: AB716666) and F19 (Accession number: KF765493).

G. mellonella phage therapy assay. Larvae of *G. mellonella* were obtained from Sa.gi.p (Sa.gi.p, Ravenna, Italy) and used after one O/N incubation at 14 °C. Larvae were inspected to select candidates weighing approximately 450–600 mg for the phage therapy assay. *G. mellonella* larvae were surface-disinfected with a cotton swab dipped in 70% ethanol (Sigma-Aldrich) and injected with 10 µl of inoculum containing 10⁷ cells of *K. pneumoniae* KKBO-1 or *K. pneumoniae* KP04C62 into the larval haemolymph behind the last proleg, by using a 30-gauge syringe (Hamilton, Reno, NV). Bacterial suspensions were prepared in 10 mM phosphate buffered saline (PBS) pH 6.5. At 30 minutes post-infection, a group of larvae was injected at the same site, but on the opposite side to the bacterial injection, with 10 µl of a φBO1E preparation at a concentration to obtain an MOI of 10 or 100. A total of 10 larvae was used for each condition. Positive (larvae infected with *K. pneumoniae* KKBO-1 or KP04C62 and treated with SM buffer) and two negative control groups (one group injected with SM buffer only and one group injected with phage suspension only) were also included. Larvae were placed into Petri dishes and incubated at 35 ± 2 °C in the dark, in humidified atmosphere, with food, and daily examined for pigmentation and mobility. Time of death was recorded at 24, 48 and 72 hours. For each experiment, the injected inoculum was checked by plating serial dilutions and enumerating colonies after 12–16 hours of incubation at 37 °C. Five independent experiments were performed for each different bacterial inoculum/phage titer combination. Data from independent experiments were pooled and the protection of larvae from death by φBO1E was assessed by log-rank (Mantel-Cox) test. *p* values < 0.05 were considered statistically significant. Statistical analyses were performed using GraphPad Prism software (GraphPad Software, Inc., La Jolla, USA).

References

- Bush, K. Alarming β-lactamase-mediated resistance in multidrug-resistant *Enterobacteriaceae*. *Curr. Opin. Microbiol.* **13**, 558–564 (2010).
- Michael, C. A., Dominey-Howes, D. & Labbate, M. The antimicrobial resistance crisis: causes, consequences, and management. *Front. Public Health* **2**, 145, doi:10.3389/fpubh.2014.00145 (2014).
- U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: <http://www.cdc.gov/drugresistance/threat-report-2013>. (Accessed: 26th January 2017) (2014).
- World Health Organization (WHO). Antimicrobial resistance: global report on surveillance. Available at: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf. (Accessed: 26th January 2017) (2014).
- Canton, R. *et al.* Rapid evolution and spread of carbapenemases among *Enterobacteriaceae* in Europe. *Clin. Microbiol. Infect.* **18**, 413–431 (2012).
- Girmentria, C. *et al.* Management of carbapenem resistant *Klebsiella pneumoniae* infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. *Haematologica* **100**, e373–e376; haematol.2015.125484 (2015).
- Lee, C. R. *et al.* Global dissemination of carbapenemase-producing *Klebsiella pneumoniae*: epidemiology, genetic context, treatment options, and detection methods. *Front. Microbiol.* **7**, 895, doi:10.3389/fmicb.2016.00895 (2016).
- Munoz-Price, L. S. *et al.* Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect. Dis.* **13**, 785–796 (2013).
- Tangden, T. & Giske, C. G. Global dissemination of extensively drug-resistant carbapenemase-producing *Enterobacteriaceae*: clinical perspectives on detection, treatment and infection control. *J. Intern. Med.* **277**, 501–512 (2015).
- Tzouveleki, L. S., Markogiannakis, A., Psychogiou, M., Tassios, P. T. & Daikos, G. L. Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: an evolving crisis of global dimensions. *Clin. Microbiol. Rev.* **25**, 682–707 (2012).
- Qi, Y. *et al.* ST11, the dominant clone of KPC-producing *Klebsiella pneumoniae* in China. *J. Antimicrob. Chemother.* **66**, 307–312 (2011).
- Tseng, I. L. *et al.* Emergence of carbapenemase producing *Klebsiella pneumoniae* and spread of KPC-2 and KPC-17 in Taiwan: a nationwide study from 2011 to 2013. *PLoS One* **10**, e0138471, doi:10.1371/journal.pone.0138471 (2015).
- Chen, L., Mathema, B., Pitout, J. D., DeLeo, F. R. & Kreiswirth, B. N. Epidemic *Klebsiella pneumoniae* ST258 is a hybrid strain. *MBio* **5**, e01355–14; mBio.01355–14 (2014).
- D'Andrea, M. M. *et al.* Diversity of capsular polysaccharide gene clusters in KPC-producing *Klebsiella pneumoniae* clinical isolates of sequence type 258 involved in the Italian epidemic. *PLoS One* **9**, e96827, doi:10.1371/journal.pone.0096827 (2014).
- Gaiarsa, S. *et al.* Genomic epidemiology of *Klebsiella pneumoniae* in Italy and novel insights into the origin and global evolution of its resistance to carbapenem antibiotics. *Antimicrob. Agents Chemother.* **59**, 389–396 (2015).
- Conte, V. *et al.* Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* from invasive infections in Italy: increasing diversity with predominance of the ST512 clade II sublineage. *J. Antimicrob. Chemother.* **71**, 3386–3391 (2016).
- Giani, T. *et al.* Epidemic diffusion of KPC carbapenemase-producing *Klebsiella pneumoniae* in Italy: results of the first countrywide survey, 15 May to 30 June 2011. *Euro Surveill.* **18**, pii=20489. Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20489> (2013).
- Kitchel, B. *et al.* Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob. Agents Chemother.* **53**, 3365–3370 (2009).
- Nordmann, P., Naas, T. & Poirel, L. Global spread of carbapenemase-producing *Enterobacteriaceae*. *Emerg. Infect. Dis.* **17**, 1791–1798 (2011).
- Wright, M. S. *et al.* Population structure of KPC-producing *Klebsiella pneumoniae* isolates from midwestern U.S. hospitals. *Antimicrob. Agents Chemother.* **58**, 4961–4965 (2014).
- Hughes, K. A., Sutherland, I. W. & Jones, M. V. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. *Microbiology* **144**, 3039–3047 (1998).
- Eriksson, H. *et al.* A suggested new bacteriophage genus, “Kp34likevirus”, within the *Autographivirinae* subfamily of *Podoviridae*. *Viruses* **7**, 1804–1822 (2015).
- Drulis-Kawa, Z. *et al.* Isolation and characterisation of KP34—a novel φKMV-like bacteriophage for *Klebsiella pneumoniae*. *Appl. Microbiol. Biotechnol.* **90**, 1333–1345 (2011).
- Cannatelli, A. *et al.* *In vivo* emergence of colistin resistance in *Klebsiella pneumoniae* producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP *mgrB* regulator. *Antimicrob. Agents Chemother.* **57**, 5521–5526 (2013).
- Arena, F. *et al.* Infections caused by carbapenem-resistant *Klebsiella pneumoniae* with hypermucoviscous phenotype: A case report and literature review. *Virulence*. doi:10.1080/21505594.2017.1286439 (2017).
- Arena, F. *et al.* Colistin resistance caused by inactivation of the *MgrB* regulator is not associated with decreased virulence of sequence type 258 KPC carbapenemase-producing *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* **60**, 2509–2512 (2016).

27. Abedon, S. T., Kuhl, S. J., Blasdel, B. G. & Kutter, E. M. Phage treatment of human infections. *Bacteriophage* **1**, 66–85 (2011).
28. Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J. & Lu, T. K. Genetically engineered phages: a review of advances over the last decade. *Microbiol. Mol. Biol. Rev.* **80**, 523–543 (2016).
29. Orndorff, P. E. Use of bacteriophage to target bacterial surface structures required for virulence: a systematic search for antibiotic alternatives. *Curr. Genet.* **62**, 753–757 (2016).
30. Domingo-Calap, P., Georgel, P. & Bahram, S. Back to the future: bacteriophages as promising therapeutic tools. *HLA* **87**, 133–140 (2016).
31. Mijalis, E. M., Lessor, L. E., Cahill, J. L., Rasche, E. S. & Kutty Everett, G. F. Complete genome sequence of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* myophage Miro. *Genome Announc.* **3**, doi:10.1128/genomeA.01137-15 (2015).
32. Meira, G. L. *et al.* Genome sequence of KP-Rio/2015, a novel *Klebsiella pneumoniae* (Podoviridae) phage. *Genome Announc.* **4**, doi:10.1128/genomeA.01298-16 (2016).
33. Pirnay, J. P. *et al.* Quality and safety requirements for sustainable phage therapy products. *Pharm. Res.* **32**, 2173–2179 (2015).
34. Bush, K. *et al.* Tackling antibiotic resistance. *Nat. Rev. Microbiol.* **9**, 894–896 (2011).
35. Szijarto, V. *et al.* Both clades of the epidemic KPC-producing *Klebsiella pneumoniae* clone ST258 share a modified galactan O-antigen type. *Int. J. Med. Microbiol.* **306**, 89–98 (2016).
36. Hsu, C. R., Lin, T. L., Pan, Y. J., Hsieh, P. F. & Wang, J. T. Isolation of a bacteriophage specific for a new capsular type of *Klebsiella pneumoniae* and characterization of its polysaccharide depolymerase. *PLoS One* **8**, e70092, doi:10.1371/journal.pone.0070092 (2013).
37. Sambrook, J. & Russell, D. W. *Molecular Cloning: A Laboratory Manual (4th Edition)*. Cold Spring Harbor, N.Y (Cold Spring Harbor Laboratory Press, 2001).
38. Horne, R. W. & Ronchetti, I. P. A negative staining-carbon film technique for studying viruses in the electron microscope. I. Preparative procedures for examining icosahedral and filamentous viruses. *J. Ultrastruct. Res.* **47**, 361–383 (1974).
39. Di Lallo, G. *et al.* Isolation and partial characterization of bacteriophages infecting *Pseudomonas syringae* pv. *actinidiae*, causal agent of kiwifruit bacterial canker. *J. Basic Microbiol.* **54**, 1210–1221 (2014).
40. Lavigne, R. *et al.* The genome of bacteriophage ϕ KMV, a T7-like virus infecting *Pseudomonas aeruginosa*. *Virology* **312**, 49–59 (2003).
41. Simpson, J. T. *et al.* ABySS: a parallel assembler for short read sequence data. *Genome Res.* **19**, 1117–1123 (2009).
42. Cox, M. P., Peterson, D. A. & Biggs, P. J. SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data. *BMC Bioinformatics* **11**, 485, doi:10.1186/1471-2105-11-485 (2010).
43. Aziz, R. K. *et al.* The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* **9**, 75, doi:10.1186/1471-2164-9-75 (2008).
44. Marchler-Bauer, A. *et al.* CDD: NCBI's conserved domain database. *Nucleic Acids Res* **43**, D222–D226, doi:10.1093/nar/gku1221 (2015).

Acknowledgements

The authors are sincerely grateful to Dr. Vivi Miriagou and to Dr. Kostas Papagiannitsis, who kindly provided some isolates used for the determination of the host range. Furthermore, we acknowledge the precious assistance of Dr. Vincenzo Di Pilato for the high throughput DNA sequencing and the contribution of Dr. Fabio Arena for the initial setup of the *G. mellonella* infection model.

Author Contributions

M.M.D. was involved in the experimental design, performed the analysis of results and wrote the manuscript. G.M.R. and M.C.T. conceived the study idea, were involved in the experimental design, wrote the manuscript and jointly supervised the work. M.M.D., M.P. and N.C. performed the bioinformatic analysis. G.D.L., P.M., N.C. and E.D. performed the characterization of the phage physiology and carried out the lysogenization experiments. E.V. and P.L. performed the TEM analysis. L.H.D.A. and M.P. were involved in the experiments with *Galleria mellonella*, including statistical analysis. All authors revised and approved the manuscript.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-02788-9

Competing Interests: The authors declare that they have no competing interests.

Accession codes: The nucleotide sequence of ϕ BO1E was deposited in the GenBank database under accession number KM576124.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017